| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PPY |
| Uniprot No | P01298 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-95aa |
| 氨基酸序列 | MAAARLCLSLLLLSTCVALLLQPLLGAQGAPLEPVYPGDNATPEQMAQYA ADLRRYINMLTRPRYGKRHKEDTLAFSEWGSPHAAVPRELSPLDL |
| 预测分子量 | 36 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PPY(Pancreatic Polypeptide)重组蛋白研究的模拟参考文献示例(内容为虚构，仅作格式参考)：
---
1. **标题**：*Recombinant Human Pancreatic Polypeptide (PPY): Expression in E. coli and Functional Characterization*
**作者**：Smith A, et al.
**摘要**：研究通过大肠杆菌系统高效表达重组人胰多肽(PPY)，优化纯化工艺，并验证其与受体结合活性，为代谢疾病研究提供工具。
---
2. **标题**：*PPY Recombinant Protein Attenuates Obesity via Regulation of Appetite Neurons*
**作者**：Chen L, et al.
**摘要**：利用哺乳动物细胞表达的重组PPY蛋白，在小鼠模型中证明其通过调控下丘脑神经元抑制食欲，改善肥胖相关代谢紊乱。
---
3. **标题**：*Structural Analysis and Stability Optimization of PPY Fusion Protein*
**作者**：Wang X, et al.
**摘要**：通过基因工程技术构建PPY-人血清白蛋白(HSA)融合蛋白，解析其晶体结构并优化稳定性，延长体内半衰期。
---
4. **标题**：*A Novel PPY Variant Recombinant Protein for Targeted Cancer Imaging*
**作者**：Kim S, et al.
**摘要**：开发基于重组PPY变体的荧光标记探针，特异性识别肿瘤细胞表面受体，为癌症早期诊断提供新策略。
---
注：以上文献为虚构示例，实际研究中请通过PubMed、Google Scholar等平台检索关键词“recombinant pancreatic polypeptide”或“PPY protein expression”获取真实文献。
**Background of Recombinant PPY (Pancreatic Polypeptide) Protein**
Pancreatic polypeptide (PPY), a 36-amino acid peptide hormone, belongs to the neuropeptide Y (NPY) family and is primarily secreted by PP cells in the pancreas. It plays a regulatory role in energy homeostasis, appetite suppression, and gastrointestinal functions by interacting with Y receptors (Y4 and Y5 subtypes). PPY’s C-terminal amidation is critical for its biological activity, influencing metabolic pathways and satiety signaling. Dysregulation of PPY has been linked to obesity, diabetes, and gastrointestinal disorders, making it a target for therapeutic research.
Recombinant PPY protein is engineered using genetic engineering techniques, typically expressed in *E. coli* or yeast systems to ensure proper folding and post-translational modifications. The recombinant form retains native PPY’s bioactivity, enabling scalable production for research and clinical applications. Its development addresses challenges in natural PPY extraction, such as low yield and high cost.
In research, recombinant PPY is used to study metabolic diseases, appetite regulation, and gut-brain axis interactions. Clinically, it holds potential as a therapeutic agent for obesity and type 2 diabetes, with studies exploring its role in reducing food intake and improving insulin sensitivity. Additionally, it serves as a diagnostic tool for pancreatic endocrine tumors. Despite progress, challenges remain in optimizing delivery methods and minimizing side effects. Ongoing research focuses on enhancing stability and receptor specificity to unlock its full therapeutic potential.
×
